 |
인쇄하기
취소
|
Next-generation dementia therapy’s Phase 3 clinical trials starts in Korea
The next generation dementia therapy, which was expected to generate approximately KRW 1 trillion prescriptions in the global market, was approved to conduct Phase 3 clinical trials in Korea.
The therapy is ‘RVT-101’ that is evaluated to follow the most popular one, ‘donepezil(product name: Aricept, Eisai).’
On the 23rd, the Ministry of Food and Drug Safety announced approval of RVT-101’s cli...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.